Biohaven Ltd. (BHVN)
(Delayed Data from NYSE)
$15.24 USD
+0.53 (3.60%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $15.25 +0.01 (0.07%) 5:04 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BHVN 15.24 +0.53(3.60%)
Will BHVN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BHVN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BHVN
Company News for Mar 4, 2025
Company News for Jan 2, 2025
BHVN: What are Zacks experts saying now?
Zacks Private Portfolio Services
SRRK Stock Soars as Muscle Disease Drug Meets Phase III Study Goal
Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More
BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal
Other News for BHVN
Janus Henderson Global Life Sciences Diversified ADR Managed Account Q2 2025 Commentary
Janus Henderson Global Life Sciences Fund Q2 2025 Commentary
Biotech stocks rise following Prasad exit from FDA
12 Health Care Stocks Moving In Wednesday's Intraday Session
Biohaven (BHVN) Shares Surge After FDA Regulatory Shift